| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1491f675b8b0bee6da136cfa0cdf3703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68355bb7e2bfbb8d08bdd04258d0aaad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bb49c4d3b3e0935fd505e6909129998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13dc24428f765c25551704b6519b98ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5cf811e10ad9068ddf72c04b69c8ba8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-723 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate |
1997-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4728c960c17c77514d15e2f33e557b9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c609d985f9fda4ccac87cb493ac850e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36179cf5b59f02a21460e70fef51ddef |
| publicationDate |
1998-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2259132-A1 |
| titleOfInvention |
Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization |
| abstract |
This invention relates to peptides and peptidomimetic compounds that modulate the function of G-protein-coupled receptors by affecting the ratio of receptor monomer to homo-oligomeric forms. Novel short peptides of a preferred length of up to about 15-20 amino acid residues are modeled on transmembrane domains of G-protein-coupled receptors, whose activities are affected by the formation of oligomers. These novel peptides and peptidomimetic compounds can be used to selectively affect the activity of G-protein-coupling receptors, thereby functioning as potential therapeutic drugs, etc.. A preferred peptide is GIIMGTFTLCWLPFFIVNIV. |
| priorityDate |
1996-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |